Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS
Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS
arcticnovartis
- Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breaker
- Scemblix data across clinical and real-world settings offer new evidence informing CML care amid evolving patient needs
- 96-week pelabresib Phase III data represent longest follow-up of first-line myelofibrosis patients in randomized combination trial